Skip to main content

Table 3 Novel targeted post-ASCT consolidative options in development or approved for use in R/R HL

From: Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

Targeted agent Treatment setting Efficacy Safety
ADCs
 Brentuximab vedotin (anti-CD30; monotherapy)
phase III AETHERA study (NCT01100502) [17, 65]
Consolidation therapy after ASCT in patients with HL at high risk of progression or relapse (n = 165 brentuximab vedotin arm) • 2-year PFS rate: 63%
• 5-year PFS rate: 59%
• Grade 3/4 AEs: 16%
• Peripheral neuropathy: 67% (90% of which had improved or completely resolved after 5 years’ follow-up)
 Camidanlumab tesirine (anti-CD25; monotherapy) phase I study (NCT00516217) [66] R/R HL (median 5 prior lines; n = 26) • ORR 81%
• CR 50%
• Grade ≥ 3 treatment-emergent adverse events: 62%
Histone deacetylase inhibitors
 Panobinostat (monotherapy)
phase III (NCT01034163) [67]
Consolidation therapy after HDC and ASCT in patients with HL at high risk of relapse (n = 27 panobinostat arm) Study discontinued early due to poor accrual (41/367 planned patients enrolled), so efficacy not formally evaluated • Grade 3/4 AEs: 65%. Most frequent:
 - Neutropenia (27%)
 - Thrombocytopenia (15%)
 - Diarrhea, vomiting, fatigue (12%)
Monoclonal antibodies
 Nivolumab (anti-PD-1; monotherapy) phase II CheckMate 205 study (NCT02181738) [68, 69] R/R cHL after ASCT and brentuximab vedotin • ORR 69% • Grade 3/4 AEs were low
 Pembrolizumab (anti-PD-1; monotherapy)
(NCT02362997) [70]
Post-ASCT consolidation therapy in patients with R/R cHL who had achieved a CR or PR with salvage chemotherapy (N = 31) • PFS rate at 18 months: 82%
• OS rate at 18 months: 100%
• Grade ≥ 2 AEs: 80%
• Grade ≥ 3 AEs: 30%
• Immune-related AEs: 43%
 Galiximab (anti-CD80) phase II CALGB 50602 study (NCT00516217) [71] R/R HL; median 3 prior regimens (n = 29) • ORR 10.3%
• Median PFS 1.6 months
• Minimal grade 3/4 toxicities
 Lucatumumab (anti-CD40) phase Ia/II study (NCT00670592) [72] R/R HL (n = 37) • ORR 13.5% • Grade 3/4 AEs: 65% (HL and NHL)
 TNX-650 (anti-IL-13) phase I/II study (NCT00441818) Refractory HL • Study in progress  
 Relatlimib (anti-LAG-3) phase I/II study with/without nivolumab (NCT02061761) R/R HL • Study in progress  
 AMG655 (anti-TRAIL) with bortezomib or vorinostat phase Ib study (NCT00791011) R/R Lymphoma • No longer in development  
 RFT5-SPMT-dgA (anti-CD25) R/R HL • No longer in development  
 Alemtuzumab (anti-CD52) phase II study with dose-adjusted-EPOCH regimen (NCT01030900) R/R HL • Study in progress (monotherapy failed)  
Bispecific antibody
 AFM13 (anti-CD30/CD16a; monotherapy) phase I study complete; phase II ongoing (NCT02321592) [73] Heavily-pretreated R/R HL (n = 28) • ORR 11.5% • Grade ≥ 3 AEs: 29%
 AFM13 (anti-CD30/CD16a; plus pembrolizumab) phase Ib KEYNOTE-206 study (NCT02665650) [74] R/R HL (failed brentuximab vedotin; n = 30) • ORR 88%
• CR 46%
• 6-month PFS 77%
• Grade 3/4 AEs included infusion-related reactions in 13%
CAR-T cells
 Anti-CD30
RELY-30 phase I study (NCT02917083) [75]
R/R HL
Median 5 prior therapies (n = 14)
• CR 58% • Not reported
 Phase Ib/II study [76] R/R HL
Median 7.5 prior therapies (n = 22)
• CR 53% • Not reported
 Phase I study
(NCT02259556) [77]
R/R HL
Heavily pretreated patients (n = 18)
• ORR 39%
• Median PFS 6 months
• Grade ≥ 3 AEs in 2 patients
 Anti-LMP1/2 phase I study
(NCT00671164) [78]
R/R HL/NHL (n = 25) • 2-year EFS 50%
• ORR 62%
• CR 52%
• Not reported
  1. EPOCH etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; NHL non Hodgkin lymphoma
\